Endocarditis, Bacterial
Recent clinical, regulatory, research and industry developments relating to this disease.
Emerging and Re-Emerging Pathogens in Valvular Infective Endocarditis: A Review.
2023 ESC Guidelines for the management of endocarditis.
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q1 2028.
Clinical MilestonesViewHide
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Endocarditis, Bacterial6
- Endocarditis5
- Communicable Diseases4
- Heart Valve Prosthesis2
- Bacteremia1
- Cardiology1
- Cardiovascular Diseases1
- Prosthesis-Related Infections1
Leading journals5
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America5
- European heart journal2
- Circulation1
- Pathogens (Basel, Switzerland)1
- The New England journal of medicine1
Leading researchers8
- Durack DT3
- Duval X3
- Hoen B3
- Karchmer AW3
- Miro JM3
- Selton-Suty C3
- Baddour LM2
- Bayer AS2
Affiliations (unnormalised)6
- Duke University Medical Center3
- Beth Israel Deaconess Medical Center2
- Duke Clinical Research Institute2
- Hospital Clinic-IDIBAPS2
- Instituto de Salud Carlos III2
- Mayo Clinic2
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Bacterial endocarditis is an inflammation of the endocardium caused by bacteria that enter the bloodstream. It most commonly involves the endocardial surface of native or prosthetic heart valves.
The immediate cause is bacterial entry into the bloodstream followed by infection of the endocardium. The bacterial strains involved vary with predisposing factors, and the literature notes a shift in causative pathogens over time, with staphylococci now often overtaking streptococci as the main pathogens.
Bacteria in the bloodstream seed the endocardial surface, producing infection and inflammation of the endocardium. The disease commonly affects heart valves, including prosthetic valves, and diagnostic literature emphasizes imaging and microbiologic methods to detect this endocardial infection.
Predisposing factors include congenital heart defects, heart valve diseases, heart valve prosthesis implantation, and intravenous drug use. Review literature also identifies degenerative valvopathies and the presence of prosthetic heart valves as important risk factors.
Management is described at the level of prevention, diagnosis, and therapy rather than specific regimens. The grounding supports prevention of infective endocarditis in high-risk settings, and treatment is generally antibiotic therapy guided by microbiology and diagnostic criteria; imaging modalities such as 18F-fluorodeoxyglucose PET and cardiac CT are used in diagnosis.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.